In January 2022, the DESTINY‐Lung01trial demonstrated clinically significant antitumor activity of trastuzumab deruxtecan (also known as T‐DXd or Enhertu) in patients with HER‐2‐mutant NSCLC. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.